Trial record 3 of 3 for:
TPIV 200,
Folate Receptor Alpha Peptide Vaccine With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02978222 |
|
Recruitment Status :
Terminated
(Futility analysis did not support continuation of the trial)
First Posted : November 30, 2016
Last Update Posted : February 20, 2020
|
Sponsor:
Marker Therapeutics, Inc.
Information provided by (Responsible Party):
Marker Therapeutics, Inc.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
This is a double-blind, randomized, parallel groups Phase II trial. Patients with platinum-sensitive advanced ovarian cancer, defined as a lack of progression by RECIST v1.1 criteria following completion of standard-of-care chemotherapy, including a minimum of 4 cycles of a platinum-containing regimen. Patients will be randomized to either the vaccine regimen with GM-CSF adjuvant or GM-CSF adjuvant alone as a control group. Treatment will be administered as a consolidation therapy within one year of the last administration of platinum, targeting the first remission.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Platinum Sensitive Ovarian Cancer Ovarian Cancer | Biological: FRα peptide plus Adjuvant (GM-CSF) Drug: Adjuvant (GM-CSF) Alone | Phase 2 |
This is a multicenter double-blind controlled randomized Phase II study to evaluate the activity of folate receptor alpha (FRα) peptide vaccine as a consolidation treatment following completion of no less than 4 cycles of a platinum containing regimen in patients with platinum-sensitive, non-mucinous ovarian, fallopian tube or primary peritoneal cancer.
The patients will have demonstrated a tumor response or stable disease upon their last regimen (per RECIST v1.1 and/or CA125 GCIG criteria) prior to enrolment in this study.
Following randomization, patients will be administered TPIV200 with GM-CSF adjuvant or GM-CSF control alone. Patients will have booster doses and tumor assessments done every 12 weeks ± 1 week for up to 1.5 years, until objective disease progression or the patient withdraws consent. Tumor responses will be assessed at the study sites by evaluating tumor images/scans according to RECIST v1.1.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 120 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | A Randomized Multicenter Phase II Trial to Evaluate the Safety, Efficacy and Immunogenicity of Vaccination With Folate Receptor Alpha Peptides With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer and a Response or Stable Disease to Platinum Therapy |
| Actual Study Start Date : | January 26, 2017 |
| Actual Primary Completion Date : | January 15, 2020 |
| Actual Study Completion Date : | January 15, 2020 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Ovarian cancer
| Arm | Intervention/treatment |
|---|---|
|
Experimental: FRα peptide plus adjuvant (GM-CSF)
FRα peptide vaccine with GM-CSF adjuvant ID administration monthly for 6 months followed by booster administrations every 3 months for up to 1.5 years
|
Biological: FRα peptide plus Adjuvant (GM-CSF)
Intradermal injection FRα peptides, 500μg each - plus GM-CSF 125 μg
Other Name: TPIV200 with GM-CSF adjuvant |
|
Placebo Comparator: Adjuvant (GM-CSF) Alone
GM-CSF adjuvant alone ID administration monthly for 6 months followed by booster administrations every 3 months for up to 1.5 years
|
Drug: Adjuvant (GM-CSF) Alone
Intradermal injection 125 μg GM-CSF
Other Name: Leukine® |
Primary Outcome Measures :
- Progression free survival [ Time Frame: 2 years ]Time to disease progression or recurrence of ovarian cancer defined as disease progression by RECIST 1.1., disease recurrence, death without progression or CA125 progression
Secondary Outcome Measures :
- Overall survival (OS) [ Time Frame: 2 years ]Death with or without ovarian cancer progression
- Best overall response rate [ Time Frame: 2 years ]Best overall response defined as sum of Complete Responses and Partial Responses in the subset of patients with measurable tumor lesions at baseline
- Disease control rate [ Time Frame: 2 years ]Disease control rate defined as the sum of Complete Responses, Partial Responses and Stable Disease
- Response Rate by immune-related RECIST (irRECIST) criteria [ Time Frame: 2years ]
- Cancer Antigen (CA)-125 response [ Time Frame: 2years ]2 fold increase from from the baseline CA125 (if above normal at baseline) or 2-fold greater than normal limits (if within normal limits at baseline)
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Criteria
Criteria for Inclusion:
- Female patient ≥ 18 years
- Willing and able to give informed consent
- Stage III-IV platinum-sensitive (defined as a lack of progression by RECIST v1.1 criteria following completion of standard-of-care chemotherapy, including a minimum of 4 cycles of a platinum-containing regimen) epithelial ovarian, fallopian tube or primary peritoneal carcinoma in first remission.
- Histologic documentation of diagnosis of carcinoma is required and the following histologic subtypes are eligible: high grade (grade ≥3+) serous or endometrioid carcinoma, carcinosarcoma, or poorly-differentiated adenocarcinoma, or mixed (including above subtypes only). Note that synchronous serous or endometrioid uterine or fallopian cancers are allowed.
- The patient must have demonstrated an objective response (PR or CR) or stable disease (SD) with the last chemotherapy prior to enrollment and this response must be stable (without progressive disease) before randomization.
- Patients must receive their first dose of vaccine within 1 year of completion of their final dose of a chemotherapeutic agent of the platinum-containing regimen
-
Adequate normal organ and marrow function within 14 days prior to first vaccine administration:
- Absolute neutrophil count > 1.5 x 109/L
- Platelet > 100 x 109/L
- Hemoglobin > 9.0 g/dL
- Serum bilirubin < 1.5 times ULN (unless Gilbert's syndrome without concurrent clinically significant liver disease
- AST/ALT < 2.5 ULN unless liver metastasis in which case it must be < 5 x ULN
- Serum creatinine CL > 40 mL/min by Cockcroft-Gault formula.
- Anti-nuclear antibody (ANA) negative or low-positive institutional range, as determined within 28 days from registration. Intermediate values (usually defined by a titer of ≤1:80, or as indicated by institutional range) are acceptable if there are, in the opinion of the Investigator, no early signs of an autoimmune disease.
- Female subjects must either be of non-reproductive potential (i.e. post-menopause by history: > 60 years old and no menses for > 12 months naturally or secondary to radiation/chemotherapy; OR serum FSH, LH and estradiol levels in the post-menopausal range; OR history of hysterectomy; OR history of bilateral tubal ligation; OR history of bilateral oophorectomy), or must have a negative serum pregnancy test upon study entry
- Life expectancy > 24 weeks
- ECOG performance status of 0 or 1
- Formalin fixed, paraffin embedded tumor sample from the primary cancer must be sent for central testing.
Criteria for Exclusion
- Histology consistent with non-serous, non-endometrioid (i.e. mucinous or clear cell), or low-grade or borderline serous ovarian carcinoma
- Patients with a history of other cancers (other than non-melanoma skin cancers [i.e. basal or squamous cell]) within the past 3 years.
- Receipt of the last dose of anti-cancer therapy (chemotherapy, immunotherapy, targeted therapy, biological/cell therapy, tumor embolization, monoclonal antibodies, other investigational agent) < 28 days prior to the first dose of study drug.
- Current or prior use of immunosuppressive medication within 28 days prior to the fist dose of study drug with the exception of topical, intranasal or inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroid.
- Active autoimmune disease requiring therapy within the past 2 years. Note: patients with vitiligo, Grave's disease or psoriasis not requiring systemic treatment within the past 2 years are not excluded.
- History of hypersensitivity to GM-CSF
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, active peptic ulcer disease or gastritis, active bleeding diatheses including any subject known to have evidence of acute or chronic hepatitis B, hepatitis C or human immunodeficiency virus (HIV), or psychiatric illness/social situations that would limit compliance with study requirements or compromise the ability of the subject to give written informed consent
- Symptomatic thyroid disease, unless negative for thyroid antibodies (TSH receptor, TPO, thyroglobulin).
- Subjects who are pregnant or are breast feeding.
-
Subjects who or of reproductive potential, and are either:
- Not abstinent;
- Not in an exclusive relationship with a partner who is surgically sterile;
- Not employing an effective method of birth control.
- Any condition that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study results
- Symptomatic or uncontrolled brain metastasis requiring concurrent treatment, inclusive of but not limited to surgery, radiation and/or corticosteroids
- Subject with uncontrolled seizures
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02978222
Locations
Show 18 study locations
Sponsors and Collaborators
Marker Therapeutics, Inc.
Investigators
| Study Director: | Richard Kenney, MD | Marker Therapeutics, Inc. |
| Responsible Party: | Marker Therapeutics, Inc. |
| ClinicalTrials.gov Identifier: | NCT02978222 |
| Other Study ID Numbers: |
FRV-004 |
| First Posted: | November 30, 2016 Key Record Dates |
| Last Update Posted: | February 20, 2020 |
| Last Verified: | February 2020 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
Additional relevant MeSH terms:
|
Ovarian Neoplasms Carcinoma, Ovarian Epithelial Hypersensitivity Endocrine Gland Neoplasms Neoplasms by Site Neoplasms Ovarian Diseases Adnexal Diseases Genital Neoplasms, Female Urogenital Neoplasms Endocrine System Diseases |
Gonadal Disorders Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Immune System Diseases Molgramostim Sargramostim Immunologic Factors Physiological Effects of Drugs Antineoplastic Agents |